Neuroglial alterations in rats submitted to the okadaic acid-induced model of dementia

Behavioural Brain Research

Volumn 226, Issue 2, 2012, Pages 420-427

  Costa, Ana Paula ^a   Tramontina, Ana Carolina ^a   Biasibetti, Regina ^a   Batassini, Cristiane ^a   Lopes, Mark William ^b   Wartchow, Krista Minéia ^a   Bernardi, Caren ^a   Tortorelli, Lucas Silva ^a   Leal, Rodrigo Bainy ^b   Gonçalves, Carlos Alberto ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Animal models; Astrogliosis; Dementia; Hippocampus; Okadaic acid; S100B

Indexed keywords

EXCITATORY AMINO ACID TRANSPORTER 2; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE AMMONIA LIGASE; GLUTAMIC ACID; GLUTATHIONE; MITOGEN ACTIVATED PROTEIN KINASE P38; OKADAIC ACID; PROTEIN S100B;

AMINO ACID METABOLISM; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN REGION; CEREBROSPINAL FLUID EXAMINATION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; ENZYME ACTIVITY; GLIA; HIPPOCAMPUS; MALE; NERVE DEGENERATION; NERVE INJURY; NEUROTOXICITY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; TISSUE DISTRIBUTION;

ANIMALS; COGNITION DISORDERS; DEMENTIA; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID TRANSPORTER 2; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE-AMMONIA LIGASE; GLUTAMIC ACID; GLUTATHIONE; HIPPOCAMPUS; HUMANS; MALE; MICROINJECTIONS; MITOGEN-ACTIVATED PROTEIN KINASES; NERVE GROWTH FACTORS; NEUROGLIA; OKADAIC ACID; OXIDATION-REDUCTION; OXIDATIVE STRESS; RATS; RATS, WISTAR; S100 PROTEINS;

EID: 81355127353     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.09.035     Document Type: Article

References (86)

1. Alzheimer's Association AA Alzheimer's disease facts and figures. Alzheimers Dement 2008, 4:110-133.
2. Weinstock M., Shoham S. Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity. J Neural Transm 2004, 111:347-366.
3. Sennvik K., Fastbom J., Blomberg M., Wahlund L.O., Winblad B., Benedikz E. Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 2000, 278:169-172.
4. Trojanowski J.Q., Vandeerstichele H., Korecka M., Clark C.M., Aisen P.S., Petersen R.C., et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement 2010, 6:230-238.
5. Silvestrelli G., Lanari A., Parnetti L., Tomassoni D., Amenta F. Treatment of Alzheimer's disease: from pharmacology to a better understanding of disease pathophysiology. Mech Ageing Dev 2006, 127:148-157.
6. Kosik K.S., Joachim C.L., Selkoe D.J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 1986, 83:4044-4048.
7. Halassa M.M., Fellin T., Haydon P.G. The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med 2007, 13:54-63.
8. Mrak R.E., Griffinbc W.S. The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease. Neurobiol Aging 2001, 22:915-922.
9. Eng L.F., Ghirnikar R.S., Lee Y.L. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res 2000, 25:1439-1451.
10. Donato R., Sorci G., Riuzzi F., Arcuri C., Bianchi R., Brozzi F., et al. S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta 2009, 1793:1008-1022.
11. Goncalves C.A., Leite M.C., Nardin P. Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin Biochem 2008, 41:755-763.
12. Nedergaard M., Takano T., Hansen A.J. Beyond the role of glutamate as a neurotransmitter. Nat Rev Neurosci 2002, 3:748-755.
13. Pope S.A., Milton R., Heales S.J. Astrocytes protect against copper-catalysed loss of extracellular glutathione. Neurochem Res 2008, 33:1410-1418.
14. Schulz J.B., Lindenau J., Seyfried J., Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 2000, 267:4904-4911.
15. Vicente E., Degerone D., Bohn L., Scornavaca F., Pimentel A., Leite M.C., et al. Astroglial and cognitive effects of chronic cerebral hypoperfusion in the rat. Brain Res 2009, 1251:204-212.
16. Craft J.M., Watterson D.M., Hirsch E., Van Eldik L.J. Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human beta-amyloid. J Neuroinflamm 2005, 2:15.
17. Lackovic Z., Rebic V., Riederer P.F. Single intracerebroventricular injection of botulinum toxin type A produces slow onset and long-term memory impairment in rats. J Neural Transm 2009, 116:1273-1280.
18. Rodrigues L., Biasibetti R., Swarowsky A., Leite M.C., Quincozes-Santos A., Quilfeldt J.A., et al. Hippocampal alterations in rats submitted to streptozotocin-induced dementia model are prevented by aminoguanidine. J Alzheimers Dis 2009, 17:193-202.
19. Swarowsky A., Rodrigues L., Biasibetti R., Leite M.C., de Oliveira L.F., de Almeida L.M., et al. Glial alterations in the hippocampus of rats submitted to ibotenic-induced lesion of the nucleus basalis magnocellularis. Behav Brain Res 2008, 190:206-211.
20. Arendt T., Holzer M., Fruth R., Bruckner M.K., Gartner U. Phosphorylation of tau, Abeta-formation, and apoptosis after in vivo inhibition of PP-1 and PP-2A. Neurobiol Aging 1998, 19:3-13.
21. He J., Yamada K., Zou L.B., Nabeshima T. Spatial memory deficit and neurodegeneration induced by the direct injection of okadaic acid into the hippocampus in rats. J Neural Transm 2001, 108:1435-1443.
22. Kamat P.K., Tota S., Saxena G., Shukla R., Nath C. Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity. Brain Res 2010, 1309:66-74.
23. Ishihara H., Martin B.L., Brautigan D.L., Karaki H., Ozaki H., Kato Y., et al. Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem Biophys Res Commun 1989, 159:871-877.
24. Cohen P., Holmes C.F., Tsukitani Y. Okadaic acid: a new probe for the study of cellular regulation. Trends Biochem Sci 1990, 15:98-102.
25. Cagnoli C.M., Kharlamov E., Atabay C., Uz T., Manev H. Apoptosis induced in neuronal cultures by either the phosphatase inhibitor okadaic acid or the kinase inhibitor staurosporine is attenuated by isoquinolinesulfonamides H-7, H-8, and H-9. J Mol Neurosci 1996, 7:65-76.
26. Zhou X.W., Gustafsson J.A., Tanila H., Bjorkdahl C., Liu R., Winblad B., et al. Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. Neurobiol Dis 2008, 31:386-394.
27. Iqbal K., Grundke-Iqbal I. Molecular mechanism of Alzheimer's neurofibrillary degeneration and therapeutic intervention. Ann N Y Acad Sci 1996, 777:132-138.
28. Braak H., Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl 1998, 53:127-140.
29. Liu F., Iqbal K., Grundke-Iqbal I., Gong C.X. Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett 2002, 530:209-214.
30. Ishiguro K., Shiratsuchi A., Sato S., Omori A., Arioka M., Kobayashi S., et al. Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett 1993, 325:167-172.
31. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40.
32. Munoz L., Ammit A.J. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology 2010, 58:561-568.
33. Paxinos G. The rat nervous system 1997, Academic Press, San Diego, CA.
34. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984, 11:47-60.
35. Vicente E., Tramontina F., Leite M.C., Nardin P., Silva M., Karkow A.R., et al. S100B levels in the cerebrospinal fluid of rats are sex and anaesthetic dependent. Clin Exp Pharmacol Physiol 2007, 34:1126-1130.
36. Leite M.C., Galland F., Brolese G., Guerra M.C., Bortolotto J.W., Freitas R., et al. A simple, sensitive and widely applicable ELISA for S100B: Methodological features of the measurement of this glial protein. J Neurosci Methods 2008, 169:93-99.
37. Tramontina F., Leite M.C., Cereser K., de Souza D.F., Tramontina A.C., Nardin P., et al. Immunoassay for glial fibrillary acidic protein: antigen recognition is affected by its phosphorylation state. J Neurosci Methods 2007, 162:282-286.
38. Gottfried C., Tramontina F., Goncalves D., Goncalves C.A., Moriguchi E., Dias R.D., et al. Glutamate uptake in cultured astrocytes depends on age: a study about the effect of guanosine and the sensitivity to oxidative stress induced by H(2)O(2). Mech Ageing Dev 2002, 123:1333-1340.
39. Thomazi A.P., Godinho G.F., Rodrigues J.M., Schwalm F.D., Frizzo M.E., Moriguchi E., et al. Ontogenetic profile of glutamate uptake in brain structures slices from rats: sensitivity to guanosine. Mech Ageing Dev 2004, 125:475-481.
40. Feoli A.M., Siqueira I., Almeida L.M., Tramontina A.C., Battu C., Wofchuk S.T., et al. Brain glutathione content and glutamate uptake are reduced in rats exposed to pre- and postnatal protein malnutrition. J Nutr 2006, 136:2357-2361.
41. Browne R.W., Armstrong D. Reduced glutathione and glutathione disulfide. Methods Mol Biol 1998, 108:347-352.
42. Oliveira C.S., Rigon A.P., Leal R.B., Rossi F.M. The activation of ERK1/2 and p38 mitogen-activated protein kinases is dynamically regulated in the developing rat visual system. Int J Dev Neurosci 2008, 26:355-362.
43. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
44. Cordova F.M., Rodrigues A.L., Giacomelli M.B., Oliveira C.S., Posser T., Dunkley P.R., et al. Lead stimulates ERK1/2 and p38MAPK phosphorylation in the hippocampus of immature rats. Brain Res 2004, 998:65-72.
45. Bjerrum O.J., Heegaard N.H.H. CRC handbook of immunoblotting of proteins 1988, vol. I. CRC Press.
46. Rigon A.P., Cordova F.M., Oliveira C.S., Posser T., Costa A.P., Silva I.G., et al. Neurotoxicity of cadmium on immature hippocampus and a neuroprotective role for p38 MAPK. Neurotoxicology 2008, 29:727-734.
47. Posser T., de Aguiar C.B., Garcez R.C., Rossi F.M., Oliveira C.S., Trentin A.G., et al. Exposure of C6 glioma cells to Pb(II) increases the phosphorylation of p38(MAPK) and JNK1/2 but not of ERK1/2. Arch Toxicol 2007, 81:407-414.
48. Arendt T., Holzer M., Fruth R., Bruckner M.K., Gartner U. Paired helical filament-like phosphorylation of tau, deposition of beta/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A. Neuroscience 1995, 69:691-698.
49. Bennett P.C., Moutsoulas P., Lawen A., Perini E., Ng K.T. Novel effects on memory observed following unilateral intracranial administration of okadaic acid, cyclosporin A, FK506 and [MeVal4]CyA. Brain Res 2003, 988:56-68.
50. Middeldorp J., Hol E.M. GFAP in health and disease. Prog Neurobiol 2011, 93:421-443.
51. Noppe M., Crols R., Andries D., Lowenthal A. Determination in human cerebrospinal fluid of glial fibrillary acidic protein, S-100 and myelin basic protein as indices of non-specific or specific central nervous tissue pathology. Clin Chim Acta 1986, 155:143-150.
52. Crols R., Saerens J., Noppe M., Lowenthal A. Increased GFAp levels in CSF as a marker of organicity in patients with Alzheimer's disease and other types of irreversible chronic organic brain syndrome. J Neurol 1986, 233:157-160.
53. Ross G.W., O'Callaghan J.P., Sharp D.S., Petrovitch H., Miller D.B., Abbott R.D., et al. Quantification of regional glial fibrillary acidic protein levels in Alzheimer's disease. Acta Neurol Scand 2003, 107:318-323.
54. Kato S., Gondo T., Hoshii Y., Takahashi M., Yamada M., Ishihara T. Confocal observation of senile plaques in Alzheimer's disease: senile plaque morphology and relationship between senile plaques and astrocytes. Pathol Int 1998, 48:332-340.
55. Le Prince G., Delaere P., Fages C., Duyckaerts C., Hauw J.J., Tardy M. Alterations of glial fibrillary acidic protein mRNA level in the aging brain and in senile dementia of the Alzheimer type. Neurosci Lett 1993, 151:71-73.
56. Pike C.J., Cummings B.J., Cotman C.W. Early association of reactive astrocytes with senile plaques in Alzheimer's disease. Exp Neurol 1995, 132:172-179.
57. Kashon M.L., Ross G.W., O'Callaghan J.P., Miller D.B., Petrovitch H., Burchfiel C.M., et al. Associations of cortical astrogliosis with cognitive performance and dementia status. J Alzheimers Dis 2004, 6:595-604. [discussion 73-81].
58. Marenholz I., Heizmann C.W., Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004, 322:1111-1122.
59. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001, 33:637-668.
60. Van Eldik L.J., Wainwright M.S. The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. Restor Neurol Neurosci 2003, 21:97-108.
61. Rothermundt M., Peters M., Prehn J.H., Arolt V. S100B in brain damage and neurodegeneration. Microsc Res Tech 2003, 60:614-632.
62. Leal R.B., Frizzo J.K., Tramontina F., Fieuw-Makaroff S., Bobrovskaya L., Dunkley P.R., et al. S100B protein stimulates calcineurin activity. Neuroreport 2004, 15:317-320.
63. Norris C.M., Kadish I., Blalock E.M., Chen K.C., Thibault V., Porter N.M., et al. Calcineurin triggers reactive/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer's models. J Neurosci 2005, 25:4649-4658.
64. Chaves M.L., Camozzato A.L., Ferreira E.D., Piazenski I., Kochhann R., Dall'Igna O., et al. Serum levels of S100B and NSE proteins in Alzheimer's disease patients. J Neuroinflamm 2010, 7:6.
65. Green A.J., Harvey R.J., Thompson E.J., Rossor M.N. Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia. Neurosci Lett 1997, 235:5-8.
66. Peskind E.R., Griffin W.S., Akama K.T., Raskind M.A., Van Eldik L.J. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int 2001, 39:409-413.
67. Petzold A., Jenkins R., Watt H.C., Green A.J., Thompson E.J., Keir G., et al. Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease. Neurosci Lett 2003, 336:167-170.
68. Steiner J., Bogerts B., Schroeter M.L., Bernstein H.G. S100B protein in neurodegenerative disorders. Clin Chem Lab Med 2011, 49:409-424.
69. Robinson S.R. Changes in the cellular distribution of glutamine synthetase in Alzheimer's disease. J Neurosci Res 2001, 66:972-980.
70. Tian G., Kong Q., Lai L., Ray-Chaudhury A., Lin C.L. Increased expression of cholesterol 24S-hydroxylase results in disruption of glial glutamate transporter EAAT2 association with lipid rafts: a potential role in Alzheimer's disease. J Neurochem 2010, 113:978-989.
71. Li S., Mallory M., Alford M., Tanaka S., Masliah E. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol 1997, 56:901-911.
72. Kim K., Lee S.G., Kegelman T.P., Su Z.Z., Das S.K., Dash R., et al. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J Cell Physiol 2010, 226:2484-2493.
73. Colton C.K., Kong Q., Lai L., Zhu M.X., Seyb K.I., Cuny G.D., et al. Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicity. J Biomol Screen 2010, 15:653-662.
74. Smith C.D., Carney J.M., Starke-Reed P.E., Oliver C.N., Stadtman E.R., Floyd R.A., et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA 1991, 88:10540-10543.
75. Le Prince G., Delaere P., Fages C., Lefrancois T., Touret M., Salanon M., et al. Glutamine synthetase (GS) expression is reduced in senile dementia of the Alzheimer type. Neurochem Res 1995, 20:859-862.
76. Robinson S.R. Neuronal expression of glutamine synthetase in Alzheimer's disease indicates a profound impairment of metabolic interactions with astrocytes. Neurochem Int 2000, 36:471-482.
77. Jellinger K.A. Recent advances in our understanding of neurodegeneration. J Neural Transm 2009, 116:1111-1162.
78. Butterfield D.A., Galvan V., Lange M.B., Tang H., Sowell R.A., Spilman P., et al. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic Biol Med 2010, 48:136-144.
79. Markesbery W.R. The role of oxidative stress in Alzheimer disease. Arch Neurol 1999, 56:1449-1452.
80. Pratico D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann N Y Acad Sci 2008, 1147:70-78.
81. Nunomura A., Castellani R.J., Zhu X., Moreira P.I., Perry G., Smith M.A. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 2006, 65:631-641.
82. Morishima Y., Gotoh Y., Zieg J., Barrett T., Takano H., Flavell R., et al. Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci 2001, 21:7551-7560.
83. Pei J.J., Gong C.X., An W.L., Winblad B., Cowburn R.F., Grundke-Iqbal I., et al. Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease. Am J Pathol 2003, 163:845-858.
84. Sun A., Liu M., Nguyen X.V., Bing G. P38 MAP kinase is activated at early stages in Alzheimer's disease brain. Exp Neurol 2003, 183:394-405.
85. Giovannini M.G., Scali C., Prosperi C., Bellucci A., Vannucchi M.G., Rosi S., et al. Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis 2002, 11:257-274.
86. Savage M.J., Lin Y.G., Ciallella J.R., Flood D.G., Scott R.W. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J Neurosci 2002, 22:3376-3385.